Phase I data from the DAREON-7 trial evaluating obrixtamig, a DLL3/CD3 T-cell engager, in combination with platinum-based chemotherapy plus etoposide as first-line therapy for DLL3-positive neuroendocrine carcinomas

Obrixtamig in combination with platinum-based chemotherapy demonstrated encouraging clinical activity in patients with DLL3-positive neuroendocrine carcinomas, with high response rates and durable disease control. The regimen showed a manageable safety profile, with adverse events consistent with its mechanism and no unexpected toxicities. These findings support further development of this combination as a potential first-line treatment option.